Cosmetic cross-reference Noindex: medium evidence

102-16-9

CAS 102-16-9

102-16-9 (CAS 102-16-9) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
1
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
102-16-9
CAS Number
102-16-9
UNII
A7LDA0CIWF
InChIKey
MIYFJEKZLFWKLZ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1303827
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 1 bioactivity row

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 31251.475000000002 nM 12 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is 102-16-9 used for in pharmaceutical contexts?

102-16-9 (CAS 102-16-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for 102-16-9?

No adverse-event association or SIDER side-effect rows are rendered for 102-16-9 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is 102-16-9 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Benzyl Phenylacetate with EU status "permitted".

What clinical phase is 102-16-9 in?

No phase 1-4 clinical development badge is rendered for 102-16-9 because the matched compound identifier rows do not contain a max-phase value.